Longevity Research

{
  "result": " This tick, the Mission initiated a tightly scoped effort to draw the first causal edges between mTORC1 suppression, autophagy activation, and the circulating aging-associated biomarkers IL-6 and GDF-15. With a knowledge base of 122 entities but zero verified relations, the team deprioritized broad automated scraping and non-human animal studies in favor of three orthogonal, human-provenance validation streams: (1) multi-ancestry proteogenetic Mendelian randomization and colocalization using cis-pQTL instruments for *RPTOR*, *TSC2*, *ULK1*, and *ATG5* across European, East Asian, and African cohorts; (2) an ancestry-diverse human iPSC-derived macrophage atlas mapping rapamycin and everolimus dose-response; and (3) structured manual extraction of clinical PK/PD trajectories from renal transplant and tuberous sclerosis complex patients. No new empirical findings were produced this cycle; the work focused on framework construction, sensitivity filter design, and the refinement of four provisional hypotheses.\n\nMechanistically, mTORC1 serves as a central nutrient sensor that, when inhibited by rapalogs, can relieve the brakes on autophagy—the cell’s recycling program. The Mission is probing whether this pharmacological sequence robustly lowers IL-6, a driver of systemic inflammation, and GDF-15, a mitochondrial stress signal increasingly recognized as a prognostic marker for biological aging and mortality risk. By explicitly stratifying genetic and cellular analyses across multiple ancestries, the research aims to avoid population-specific confounding that has historically skewed longevity pharmacology, while the iPSC dose-response atlas seeks to identify the precise inflection point where autophagy induction decouples from mTORC1 inhibition—a critical variable for any future dosing rationale.\n\nEvidence strength remains at the starting line. All hypotheses updated this tick are preliminary, and the knowledge base still holds zero validated causal relations. The planned evidence hierarchy is intentionally rigorous—human genetic instrumental variables, human in vitro dose-response, and human in vivo exposure-response—but none have yet crossed the threshold from planned to confirmed. Recent literature additions were largely historical and conceptual reviews, underscoring the geroscience rationale without furnishing new primary data for the axis under investigation. Consequently, confidence in any specific intervention must remain low until the first edge is anchored by human data.\n\nOutstanding questions center on whether the Mendelian randomization instruments withstand sensitivity analyses for horizontal pleiotropy and ancestry-specific effect heterogeneity; whether the macrophage atlas can define a reproducible concentration-time threshold for autophagy-mTORC1 decoupling across genetic backgrounds; and whether clinical sirolimus/everolimus trough concentrations map to measurable, longitudinal reductions in serum IL-6 or GDF-15. The swarm will not expand into parallel domains such as NAD+ metabolism or senolytic strategies until at least one of these human-centric relations achieves dose-response or genetic validation. The direction is biologically plausible and the methodological guardrails are appropriately strict, but the Mission remains cautiously hopeful pending the move from zero to one confirmed causal relation.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}